These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10933655)

  • 1. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals.
    Ikäheimo I; Syrjälä H; Karhukorpi J; Schildt R; Koskela M
    J Antimicrob Chemother; 2000 Aug; 46(2):287-90. PubMed ID: 10933655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic susceptibility in vitro of Francisella tularensis subsp. holarctica isolates from Germany.
    Tomaso H; Hotzel H; Otto P; Myrtennäs K; Forsman M
    J Antimicrob Chemother; 2017 Sep; 72(9):2539-2543. PubMed ID: 28605439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of Francisella tularensis subsp. holarctica strains isolated from humans in the Central Anatolia region of Turkey.
    Yesilyurt M; Kiliç S; Celebi B; Celik M; Gül S; Erdogan F; Ozel G
    J Antimicrob Chemother; 2011 Nov; 66(11):2588-92. PubMed ID: 21856791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic susceptibility of Francisella tularensis subsp. holarctica strains isolated from tularaemia patients in France between 2006 and 2016.
    Caspar Y; Hennebique A; Maurin M
    J Antimicrob Chemother; 2018 Mar; 73(3):687-691. PubMed ID: 29253157
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Caspar Y; Maurin M
    Front Cell Infect Microbiol; 2017; 7():122. PubMed ID: 28443249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of isolates of Francisella tularensis from Turkey.
    Kiliç S; Celebi B; Acar B; Ataş M
    Scand J Infect Dis; 2013 May; 45(5):337-41. PubMed ID: 23249114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility of Francisella tularensis subsp. holarctica strains from Hungary, Central Europe.
    Kreizinger Z; Makrai L; Helyes G; Magyar T; Erdélyi K; Gyuranecz M
    J Antimicrob Chemother; 2013 Feb; 68(2):370-3. PubMed ID: 23065699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains.
    Tomaso H; Al Dahouk S; Hofer E; Splettstoesser WD; Treu TM; Dierich MP; Neubauer H
    Int J Antimicrob Agents; 2005 Oct; 26(4):279-84. PubMed ID: 16143497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In Vitro Activity of Tigecycline Against Francisella tularensis Subsp. holarctica in Comparison with Doxycycline, Ciprofloxacin and Aminoglycosides].
    Ulu Kılıç A; Kılıç S; Celebi B; Sencan I
    Mikrobiyol Bul; 2013 Jan; 47(1):189-91. PubMed ID: 23390918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardized broth microdilution antimicrobial susceptibility testing of Francisella tularensis subsp. holarctica strains from Europe and rare Francisella species.
    Georgi E; Schacht E; Scholz HC; Splettstoesser WD
    J Antimicrob Chemother; 2012 Oct; 67(10):2429-33. PubMed ID: 22763567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of fluoroquinolone resistance associated with DNA gyrase mutations in Francisella tularensis, including in tularaemia patients with treatment failure.
    Sutera V; Hoarau G; Renesto P; Caspar Y; Maurin M
    Int J Antimicrob Agents; 2017 Sep; 50(3):377-383. PubMed ID: 28689870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis.
    Johansson A; Urich SK; Chu MC; Sjöstedt A; Tärnvik A
    Scand J Infect Dis; 2002; 34(5):327-30. PubMed ID: 12069013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.
    Urich SK; Petersen JM
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2276-8. PubMed ID: 18411318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility pattern of Scandinavian Francisella tularensis isolates with regard to oral and parenteral antimicrobial agents.
    Scheel O; Hoel T; Sandvik T; Berdal BP
    APMIS; 1993 Jan; 101(1):33-6. PubMed ID: 8384458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antibiotic susceptibility of Francisella tularensis isolates from Japan.
    Hotta A; Fujita O; Uda A; Sharma N; Tanabayashi K; Yamamoto Y; Yamada A; Morikawa S
    Jpn J Infect Dis; 2013; 66(6):534-6. PubMed ID: 24270145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First isolation of Francisella tularensis subsp. tularensis in Europe.
    Gurycová D
    Eur J Epidemiol; 1998 Dec; 14(8):797-802. PubMed ID: 9928875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of a new group of Francisella tularensis subsp. holarctica in Switzerland with altered antimicrobial susceptibilities, 1996 to 2013.
    Origgi FC; Frey J; Pilo P
    Euro Surveill; 2014 Jul; 19(29):. PubMed ID: 25080140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of field isolates of Francisella tularensis subsp. holarctica recovered in Spain to several antimicrobial agents.
    García del Blanco N; Gutiérrez Martín CB; de la Puente Redondo VA; Rodríguez Ferri EF
    Res Vet Sci; 2004 Jun; 76(3):195-8. PubMed ID: 15046952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bis-indolic compounds as potential new therapeutic alternatives for tularaemia.
    Caspar Y; Sutera V; Boisset S; Denis JN; Maurin M
    Front Cell Infect Microbiol; 2014; 4():24. PubMed ID: 24579066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and classification of different isolates of Francisella tularensis.
    Mörner T; Mattsson R; Forsman M; Johansson KE; Sandström G
    Zentralbl Veterinarmed B; 1993 Dec; 40(9-10):613-20. PubMed ID: 7510445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.